Compugen Ltd. (CGEN)
NASDAQ (CM) NASDAQ (CM) Primary 
TASE Summary
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Compugen (CGEN) This Year?
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Compugen: Better Runway Ahead Of MAIA
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway materially improves its risk-reward profile. A positive randomized readout could help validate COM701, and it would be a win for CGEN's broader PVRIG approach.
Compugen Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 140,600 | $276,377.53 | $330,410 | $54,032.47 | 19.55% |
 Point72 Asset Management LP Point72 Asset Management LP | 11,901 | $25,468 | $28,681.41 | $3,213.41 | 12.62% |
 Jeff Ameen Spire Wealth Management | 6,564 | $14,178.24 | $15,425.4 | $1,247.16 | 8.8% |
 Taylor Fairman Eagle Rock Investment Company LLC | 71,212 | $134,444.02 | $167,348.2 | $32,904.18 | 24.47% |
 Taro Kuriyama Axq Capita LLP | 22,724 | $48,402.03 | $53,401.4 | $4,999.37 | 10.33% |
Compugen Ltd. (CGEN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Compugen Ltd. ever had a stock split?
Compugen Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Eran Ophir CEO | NASDAQ (CM) Exchange | M25722105 CUSIP |
| IL Country | 75 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Compugen Ltd. operates as a clinical-stage therapeutic discovery and development company, based in Holon, Israel, with active research and development efforts across Israel, the United States, and Europe. Specializing in the field of immuno-oncology, Compugen focuses on the research, development, and commercialization of novel therapeutic and product candidates. Leveraging cutting-edge technologies, the company dedicates its efforts to addressing various cancers through a range of promising therapeutic antibodies. Compugen has established multiple collaboration agreements with leading pharmaceutical companies and research institutions including Bayer Pharma AG, Bristol-Myers Squibb, and Johns Hopkins School of Medicine, highlighting its significant role in advancing immuno-oncology therapeutics towards commercialization. Founded in 1993, Compugen stands at the forefront of immunotherapy research aiming to bring innovative treatments to patients worldwide.
Products and Services
COM701: An anti-PVRIG antibody, currently in Phase I clinical study for treating solid tumors. COM701 aims to modulate the immune system response against tumor cells, marking a significant step in immuno-oncology.
COM902: A therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study. Focused on advanced malignancies, COM902 is tested through sequential dose escalations seeking to enhance immune cell activity against cancers.
Bapotulimab: Targets ILDR2 and is in Phase I clinical study for patients with naïve head and neck squamous cell carcinoma. This therapeutic antibody is another innovative approach to stimulate the immune system's ability to fight cancer.
Rilvegostomig: A novel anti-TIGIT/PD-1 bispecific antibody in Phase II clinical study, targeting patients with advanced or metastatic non-small cell lung cancer. Rilvegostomig represents a dual-focused immuno-oncology strategy, blocking two critical immune-inhibitory pathways.
Early-stage Immuno-oncology Programs: Include a range of projects focused to address various mechanisms of immune resistance. These programs are designed to explore newer therapeutics that could overcome challenges faced by current treatments.
COM503: An antibody that blocks the interaction between IL-18 binding protein and IL-18, signifying a high affinity antibody approach to modulate immune responses against cancerous cells.
